Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Invicta DiagnosticNSE:INVICTA +3.88%22 EBITDA Margin % is 23.06% as of Mar. 2026, which is 29% below its 10-year median of 32.30. GuruFocus rates NSE:INVICTA with a GF Score™ of 22/100. The stock has 3 warning signs investors should review. Among 202 Medical Diagnostics & Research companies, Invicta Diagnostic ranks better than 91.58% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Invicta Diagnostic's EBITDA for the
six
months ended in Mar. 2026 was ₹35.5 Mil. Invicta Diagnostic's Revenue for the
six
months ended in Mar. 2026 was ₹154.1 Mil. Therefore, Invicta Diagnostic's EBITDA margin for the quarter that ended in Mar. 2026 was 23.06%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Invicta Diagnostic EBITDA Margin % Related Terms
Invicta Diagnostic EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Invicta Diagnostic's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Invicta Diagnostic EBITDA Margin % Chart
Invicta Diagnostic Annual Data
Trend
Mar24
Mar25
Mar26
EBITDA Margin %
44.93
30.85
32.30
Invicta Diagnostic Semi-Annual Data
Mar24
Mar25
Sep25
Mar26
EBITDA Margin %
0.00
0.00
40.70
23.06
NSE:INVICTA vs TMO, DHR, IDXX: EBITDA Margin % Comparison
For the Diagnostics & Research subindustry, Invicta Diagnostic's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Invicta Diagnostic EBITDA Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Invicta Diagnostic's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Invicta Diagnostic's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Invicta Diagnostic (NSE:INVICTA) has a EBITDA Margin % of 23.06% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Invicta Diagnostic and its competitors. This is 29% below median its historical median of 32.30. Over the past decade, Invicta Diagnostic's EBITDA Margin % has ranged from 30.85 to 44.93. According to the industry distribution chart, Invicta Diagnostic ranks #17 out of 202 companies in the Medical Diagnostics & Research industry, placing it in the top 8.4%.
Is Invicta Diagnostic's EBITDA Margin % too high?
Invicta Diagnostic's current EBITDA Margin % of 23.06% is 29% below median its 10-year median of 32.30. Over the past 10 years, this metric has ranged from a low of 30.85 to a high of 44.93. The Medical Diagnostics & Research industry median EBITDA Margin % is 5.22. Invicta Diagnostic's value of 23.06% is 342.2% above this industry median. Based on the distribution chart, Invicta Diagnostic ranks #17 out of 202 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Invicta Diagnostic has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Invicta Diagnostic's EBITDA Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Invicta Diagnostic ranks #17 out of 202 companies for EBITDA Margin %. This places Invicta Diagnostic in the top 8% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 5.22. Invicta Diagnostic's value of 23.06% is 342.2% above this benchmark. Historically, Invicta Diagnostic's own EBITDA Margin % has ranged from 30.85 to 44.93 over the past decade. While the company's 10-year median is 32.30 vs. the industry median of 5.22, Invicta Diagnostic has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Diagnostics & Research company?
The median EBITDA Margin % among Medical Diagnostics & Research companies is 5.22, based on 202 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Invicta Diagnostic's current EBITDA Margin % of 23.06% is 342.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Invicta Diagnostic and its competitors. For the Medical Diagnostics & Research industry, the median EBITDA Margin % is 5.22 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Invicta Diagnostic's current EBITDA Margin % is 23.06%, which is 29% below median its own 10-year median of 32.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Invicta Diagnostic stock overvalued right now?
Invicta Diagnostic (NSE:INVICTA) has a current EBITDA Margin % of 23.06%. The current EBITDA Margin % is 23.06%, which is 29% below median its 10-year median of 32.30 and 342.2% above the Medical Diagnostics & Research industry median of 5.22. Invicta Diagnostic's overall GF Score™ is 22/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Invicta Diagnostic (NSE:INVICTA), the current EBITDA Margin % is 23.06% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Invicta Diagnostic Ltd is engaged in the business of medical and diagnostic services and operates diagnostic centres providing medical testing and allied healthcare services in the Mumbai Metropolitan Region. The Company runs a diagnostic chain comprising seven diagnostic centres and one centralised laboratory across MMR in Maharashtra and operates under a hub and spoke model with a flagship hub in Thane, additional hub centres, spoke centres, and a centralised laboratory. Its service offerings include radiology and imaging, pathology and clinical laboratory tests, teleradiology, and services such as ultrasound, X Ray, CT scan, MRI scan, PET scan, and cardiac diagnostics, with patient convenience supported through home sample collection, house calls, and multiple report delivery options.
22GF Score
Get the complete analysis for NSE:INVICTA
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:INVICTA has been successfully added to your 
